Answers are grounded in this paper and cite their sources.
Case report reveals atypical hemolytic uremic syndrome after acute type A aortic dissection, highlighting the therapeutic role of complement inhibition.
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA)-related disease that manifests as a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) and is caused by uncontrolled activation of the complement system. We report the case of a 61-year-old woman with acute type A aortic dissection that subsequently developed into aHUS. The hematologic disorders underlying aHUS improved after treatment with the complement inhibitor eculizumab. It is important to consider aHUS when a patient clinically develops a triad of microangiopathic hemolytic anemia, thrombocytopenia, and an increasing creatinine level following cardiovascular surgery.
No takes yet. Share an insight, caveat, or question.
Ikushima et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: